American Diversified Holdings Corp (ADHC)

$0.00 0.00 (-20.00%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 27,647,201
Avg Vol 23,283,469
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 57%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

American Diversified Holdings Corporation provides executive management, corporate governance, administrative support, and financial advisory services. The company also offers introductions to capital sources. It primarily serves various micro-cap public companies. The company was formerly known as Cost Containment Technologies, Inc., and changed its name to American Diversified Holdings Corporation in October 2007. American Diversified Holdings Corporation was incorporated in 2001 and is based...

Industry: Consulting Services
Sector: Industrials
Phone: 858-259-4534
Address:
122 15th Street, Suite 2568, Del Mar, United States
Hiroshi_nas
Hiroshi_nas Apr. 5 at 12:58 PM
$ADHC MONDAY PREP – APRIL 5, 2026 The April 1 announcement that GlucoGuard retained a global CRO for FDA-required patient studies (integrating Dexcom CGM tech) continues to build underlying strength. This is a major regulatory milestone for the AI-powered oral device targeting nocturnal hypoglycemia — clearing a key path toward Breakthrough Device Designation in a massive diabetes market with zero direct competition. After the strong volume reaction, shares pulled back to the ~$0.0010 level on profit-taking — creating what could be an attractive dip-buying opportunity ahead of next week’s expected PR updates in the multi-week rollout. Thin float micro-cap setup means fresh catalysts could drive a sharp rebound toward $0.0015 and higher. Regulatory progress + AI diabetes tech = real upside potential building. Adding on the dip or watching for the next catalyst on $ADHC? Drop your thoughts 👇 #ADHC #GlucoGuard #DiabetesTech #OTC @SuperRobot
0 · Reply
Hiroshi_nas
Hiroshi_nas Apr. 4 at 3:54 PM
$ADHC WEEKEND WATCH – APRIL 4, 2026 GlucoGuard’s recent move to retain a global CRO for FDA patient studies (with Dexcom CGM integration) is a strong step forward. This multi-patient trial advances the AI-powered oral device targeting nocturnal hypoglycemia — positioning $ADHC closer to Breakthrough Device Designation in a massive diabetes market with zero direct competition. After pulling back to the $0.0010 area on light profit-taking, the thin float micro-cap ($2.5M market cap) looks primed for a rebound as the multi-week PR rollout continues next week. Strong volume on the April 1 news showed real interest — any fresh update could spark a solid move back toward $0.0015 and beyond. AI + diabetes tech with real regulatory momentum building. High risk / high reward speculative play with upside potential. DYOR — not financial advice. Bullish on $ADHC heading into next week or adding on this dip? Let’s hear it 👇 #ADHC #GlucoGuard #OTC @SuperRobotGX @ADHCMANAGEMENT
0 · Reply
PrnceMichael
PrnceMichael Apr. 2 at 7:48 PM
$ADHC "After extensive research we have devised a plan with a global Contract Research Organization that has the technical know-how and access to patients in order to fulfill the FDA request," commented ADHC. "We expect to begin the Patient Studies in the near term pending normal scheduling issues." https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
UltimateTrader_22
UltimateTrader_22 Apr. 2 at 3:02 PM
$ADHC CRO to Incorporate DEXCOM's Continuous Glucose Monitoring "CGM" Technology In the GlucoGuard Multi Patient Study Del Mar, California--(Newsfile Corp. - April 1, 2026) - American Diversified Holdings Corporation (OTCID: ADHC) announce today that GlucoGuard has retained a internationally recognized Contract Research Organization (CRO) to begin its patient studies to establish safety and efficacy concerns as required by the FDA. The Scope of Work agreement will comply with the FDA's requests to gain approval. The FDA had indicated during previous meetings that all criterion were met to approve the BreakThrough Device (BTD) Application. The only remaining concerns were about a sleeping patient potentially aspirating on glucose gel into the buccal cavity. Additionally, the FDA requested a recording of the patient's glucose level before and after the administration of the glucose to determine if the patient would meet end points required
0 · Reply
Itsjustarash
Itsjustarash Apr. 2 at 2:21 PM
$ADHC what is the OS count?
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 2 at 1:41 PM
$ADHC .0012 going here..looking to bounce back
1 · Reply
BCNstocks
BCNstocks Apr. 2 at 1:29 PM
$ADHC nice news out yesterday. Plan to add at these levels and hold, as I expect more updates are coming soon. American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
em7568
em7568 Apr. 2 at 1:08 PM
$ADHC AI-Powered Diabetes Innovation: The ADHC Story https://allcapresearch.com/f/ai-powered-diabetes-innovation-the-adhc-story American Diversified Holdings Corporation (OTC: ADHC) is positioning itself at the intersection of healthcare technology and artificial intelligence through its flagship innovation, GlucoGuard. #Diabetes #GlucoGuard
0 · Reply
Zorch305
Zorch305 Apr. 2 at 1:02 PM
$ADHC https://x.com/ADHCMANAGEMENT/status/2039688823530266667
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 2 at 10:25 AM
$ADHC Chart remains bullish as support at the 20 Day MA remains strong..profit takers moving on and let’s see it this can get back over the 200 MA..
0 · Reply
Latest News on ADHC
No data available.
Hiroshi_nas
Hiroshi_nas Apr. 5 at 12:58 PM
$ADHC MONDAY PREP – APRIL 5, 2026 The April 1 announcement that GlucoGuard retained a global CRO for FDA-required patient studies (integrating Dexcom CGM tech) continues to build underlying strength. This is a major regulatory milestone for the AI-powered oral device targeting nocturnal hypoglycemia — clearing a key path toward Breakthrough Device Designation in a massive diabetes market with zero direct competition. After the strong volume reaction, shares pulled back to the ~$0.0010 level on profit-taking — creating what could be an attractive dip-buying opportunity ahead of next week’s expected PR updates in the multi-week rollout. Thin float micro-cap setup means fresh catalysts could drive a sharp rebound toward $0.0015 and higher. Regulatory progress + AI diabetes tech = real upside potential building. Adding on the dip or watching for the next catalyst on $ADHC? Drop your thoughts 👇 #ADHC #GlucoGuard #DiabetesTech #OTC @SuperRobot
0 · Reply
Hiroshi_nas
Hiroshi_nas Apr. 4 at 3:54 PM
$ADHC WEEKEND WATCH – APRIL 4, 2026 GlucoGuard’s recent move to retain a global CRO for FDA patient studies (with Dexcom CGM integration) is a strong step forward. This multi-patient trial advances the AI-powered oral device targeting nocturnal hypoglycemia — positioning $ADHC closer to Breakthrough Device Designation in a massive diabetes market with zero direct competition. After pulling back to the $0.0010 area on light profit-taking, the thin float micro-cap ($2.5M market cap) looks primed for a rebound as the multi-week PR rollout continues next week. Strong volume on the April 1 news showed real interest — any fresh update could spark a solid move back toward $0.0015 and beyond. AI + diabetes tech with real regulatory momentum building. High risk / high reward speculative play with upside potential. DYOR — not financial advice. Bullish on $ADHC heading into next week or adding on this dip? Let’s hear it 👇 #ADHC #GlucoGuard #OTC @SuperRobotGX @ADHCMANAGEMENT
0 · Reply
PrnceMichael
PrnceMichael Apr. 2 at 7:48 PM
$ADHC "After extensive research we have devised a plan with a global Contract Research Organization that has the technical know-how and access to patients in order to fulfill the FDA request," commented ADHC. "We expect to begin the Patient Studies in the near term pending normal scheduling issues." https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
UltimateTrader_22
UltimateTrader_22 Apr. 2 at 3:02 PM
$ADHC CRO to Incorporate DEXCOM's Continuous Glucose Monitoring "CGM" Technology In the GlucoGuard Multi Patient Study Del Mar, California--(Newsfile Corp. - April 1, 2026) - American Diversified Holdings Corporation (OTCID: ADHC) announce today that GlucoGuard has retained a internationally recognized Contract Research Organization (CRO) to begin its patient studies to establish safety and efficacy concerns as required by the FDA. The Scope of Work agreement will comply with the FDA's requests to gain approval. The FDA had indicated during previous meetings that all criterion were met to approve the BreakThrough Device (BTD) Application. The only remaining concerns were about a sleeping patient potentially aspirating on glucose gel into the buccal cavity. Additionally, the FDA requested a recording of the patient's glucose level before and after the administration of the glucose to determine if the patient would meet end points required
0 · Reply
Itsjustarash
Itsjustarash Apr. 2 at 2:21 PM
$ADHC what is the OS count?
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 2 at 1:41 PM
$ADHC .0012 going here..looking to bounce back
1 · Reply
BCNstocks
BCNstocks Apr. 2 at 1:29 PM
$ADHC nice news out yesterday. Plan to add at these levels and hold, as I expect more updates are coming soon. American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
em7568
em7568 Apr. 2 at 1:08 PM
$ADHC AI-Powered Diabetes Innovation: The ADHC Story https://allcapresearch.com/f/ai-powered-diabetes-innovation-the-adhc-story American Diversified Holdings Corporation (OTC: ADHC) is positioning itself at the intersection of healthcare technology and artificial intelligence through its flagship innovation, GlucoGuard. #Diabetes #GlucoGuard
0 · Reply
Zorch305
Zorch305 Apr. 2 at 1:02 PM
$ADHC https://x.com/ADHCMANAGEMENT/status/2039688823530266667
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 2 at 10:25 AM
$ADHC Chart remains bullish as support at the 20 Day MA remains strong..profit takers moving on and let’s see it this can get back over the 200 MA..
0 · Reply
em7568
em7568 Apr. 1 at 4:01 PM
$ADHC added some on the dip to .0012. Company going in the right direction and I expect more updates. https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
Stockprofiler
Stockprofiler Apr. 1 at 2:27 PM
$ADHC $DXCM $ADHC News. #FDA #Glucoguard #Wellness #OTC @ADHCMANAGEMENT
0 · Reply
BuckSlayer
BuckSlayer Apr. 1 at 2:19 PM
$ADHC 👊
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 1 at 1:56 PM
$ADHC .0015 wall cleared..could see .002 test incoming..
0 · Reply
scantant214
scantant214 Apr. 1 at 1:25 PM
$ADHC paytience!!!
0 · Reply
St0ckman691
St0ckman691 Apr. 1 at 1:23 PM
$ADHC JUST DROPPED MAJOR NEWS TODAY! GlucoGuard (ADHC’s flagship division) has officially retained a top-tier Global Contract Research Organization (CRO) to kick off critical Patient Studies — the next major milestone required for FDA clearance of their groundbreaking nocturnal glucose monitoring & delivery system! This is the exact step that moves them from development into full clinical validation and commercialization path. Even better? GlucoGuard already has Level 2 app integration live through $DXCM’s Developer Partner Program, giving it seamless, real-time access to Dexcom’s industry-leading CGM data. $DXCM = the gold standard in continuous glucose monitoring. $ADHC = the smart-money play riding that tech straight into the exploding diabetes market. https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
BCNstocks
BCNstocks Apr. 1 at 1:21 PM
$ADHC Nice news. #Diabetes #GlucoGuard $ADHC’s GlucoGuard is advancing into a critical next phase, retaining a globally recognized CRO to initiate FDA-required patient studies. These studies are focused on resolving the final outstanding items—primarily safety (aspiration risk) and efficacy (raising glucose levels from hypoglycemia). Notably, prior neonatal research already demonstrated positive outcomes, which may help de-risk this stage. https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
AveraveJoeTrader
AveraveJoeTrader Apr. 1 at 1:20 PM
News looks good for $ADHC and they also have a partnership with $DXCM a NASDAQ company that makes me think this company is making strong strides.. https://x.com/autumnsdad1/status/2039330731369861322?s=61
0 · Reply
em7568
em7568 Apr. 1 at 1:07 PM
$ADHC news out! American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
St0ckman691
St0ckman691 Apr. 1 at 1:01 PM
$ADHC news! https://finance.yahoo.com/sectors/healthcare/articles/american-diversified-holdings-operating-division-123000539.html
0 · Reply
TechnicalSniper777
TechnicalSniper777 Apr. 1 at 12:57 PM
$ADHC Patient studies begin. Big news for an OTC company. FDA approval one step closer as they begin their marketing campaign rollout.
0 · Reply
bifmik78
bifmik78 Apr. 1 at 12:54 PM
$ADHC News out. https://www.newsfilecorp.com/release/290821/American-Diversified-Holdings-Operating-Division-GlucoGuard-Retains-Global-Contract-Research-Organization-CRO-to-Begin-Patient-Studies-as-Required-by-the-FDA
0 · Reply